Ribon Therapeutics, Inc.
Records under this name other than the patents Ribon Therapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Back to Ribon Therapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,562,891 | Quinazolinones as PARP14 Inhibitors now held by AbbVie Biotechnology Ltd. In force · High confidence | In force | High confidence | |
| US 11,008,308 | Quinazolinones as PARP14 Inhibitors now held by AbbVie Biotechnology Ltd. In force · Low confidence | In force | Low confidence | |
| US 11,958,837 | Quinazolinones as PARP14 Inhibitors now held by AbbVie Biotechnology Ltd. In force · Low confidence | In force | Low confidence | |
| US 11,293,927 | Screening Methods for Parp Modulators now held by AbbVie Biotechnology Ltd. In force · High confidence | In force | High confidence | |
| US 11,535,621 | Heterobicyclic Amides as Inhibitors of CD38 now held by Boehringer Ingelheim International GmbH In force · High confidence | In force | High confidence | |
| US 11,987,584 | Heterobicyclic Amides as Inhibitors of CD38 now held by Boehringer Ingelheim International GmbH In force · High confidence | In force | High confidence | |
| US 11,952,377 | Quinolines and Azaquinolines as Inhibitors of CD38 now held by Boehringer Ingelheim International GmbH In force · High confidence | In force | High confidence | |
| 17/586,962 | Methods of Treating Inflammatory Diseases now held by AbbVie Biotechnology Ltd. Abandoned Abandoned May 7, 2024 | Abandoned | Abandoned May 7, 2024 | |
| 17/619,459 | Targeted Protein Degradation of PARP14 for Use in Therapy now held by AbbVie Biotechnology Ltd. Abandoned Abandoned Jul 28, 2025 | Abandoned | Abandoned Jul 28, 2025 | |
| 17/671,714 | Dosage Regimens for PARP7 Inhibitors Abandoned Abandoned Oct 18, 2023 | Abandoned | Abandoned Oct 18, 2023 |